PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION
https://doi.org/10.20996/1819-6446-2014-10-6-617-624
Abstract
Aim. To analyze pharmacotherapy of cerebral infarction in patients with atrial fibrillation (AF) in real clinical practice of neurological departments of Saratov hospitals.
Material and methods. A retrospective longitudinal pharmacoepidemiologic study was carried out. Medical cards were analyzed in patients with cerebral infarction and atrial fibrillation treated in neurology departments from 01.01.2009 to 31.12.2011.
Results. Acetylsalicylic acid was prescribed to 66.7% of patients, warfarin – 3.9%. At that target level of international normalised ratio was reached only in 40% of patients. It has been shown frequent (96%) prescriptions of metabolic, neuroprotective and vasoactive drugs with low level of efficacy evidence. Beta-blockers (in 39.3% of patients) and their combination with digoxin (18.7%) were prescribed for heart rate control.
Conclusion. Generally, in real clinical practice doctor’s choice of pharmacotherapy of cerebral infarction in patients with AF is not exactly in line with contemporary guidelines. These patients are frequently prescribed drugs with low efficacy and level of evidence.
About the Authors
N. V. Mikheeva
Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
O. V. Reshetko
Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
N. V. Furman
Saratov Research Institute of Cardiology
Russian Federation
Chernyshevskogo ul. 141, Saratov, 410028 Russia
Russian Federation
Chernyshevskogo ul. 141, Saratov, 410028 Russia
References
1. Oganov RG, Salimov VA, Boqueria LA, et al. Clinical practice guidelines for the diagnosis and management of patients with atrial fibrillation. Vestnik Aritmologii 2010;59:53-77. Russian (Оганов Р.Г., Салимов В.А., Бокерия Л.А. и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестник Аритмологии 2010;59:53-77).
2. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2014;45:2160- 2236.
3. Furie KL, Goldstein LB, Albers GW, et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2012;43:3442-53.
4. Ostrovskaja VO. Evaluation clinical practice: patients with acute cerebral ischemia. Lekarstvennyy Vestnik 2012;6(46)6:31-38. Russian (Островская В.О. Оценка реальной клинической практики: лечение пациентов с острым нарушением мозгового кровообращения. Лекарственный Вестник 2012;6(46)6:31-38).
5. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008;25:457-507.
6. Gusev EI, Konovalov AN, Skvortsov VI, et. al. Neurology. National leadership. Moscow: GEOTAR Media; 2009. Russian (ГусевЕ.И., КоноваловА.Н., СкворцоваВ.И., ГехтА.Б. Неврология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009).
7. Adams HP, Zoppo G, Alberts MJ, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke 2007;38:1655-711.
8. Adams RJ, Albers G, Alberts MJ, et. al. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2008;39:1647-52.
9. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American HeartAssociation/ American Stroke Association. Stroke 2011;42:227-76.
10. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
11. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-23.
12. Chuchalin AG, Belousov YB, Yasnetsov VV. Federal guidelines on the use of drugs ( formulary system). Issue X. Moscow: Echo; 2009. Russian (Чучалин А.Г., Белоусов Ю.Б., Яснецов В.В. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск Х. М.: Эхо; 2009).
13. Martsevich SY, Kutishenko NP, Tolpygina SN, et al. Efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease Recommendations, RSC 2011. Ration Pharmacother Cardiol 2011;7(5):2-72. Russian (Марцевич С.Ю., Кутишенко Н.П., Толпыгина С.Н. и др. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рекомендации ВНОК, 2011. Рациональная Фармакотерапия в Кардиологии 2011;7(5):2-72).
14. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
15. The ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-78.
16. Suslinа ZA, Varakin YY, Vereshchagin NV. Cerebrovascular diseases: Epidemiology. Framework for prevention. Moscow: MEDpress-Inform, 2009. Russian (Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга: Эпидемиология. Основы профилактики. М.: МЕД-пресс-информ, 2009).
17. Bidenko MA, Shprakh VV. Assessment of the quality of medical care according to cerebral stroke hospital register in Irkutsk. Sibirskiy Meditsinskiy Zhurnal 2009; 2:68-70. Russian (Биденко М.А., Шпрах В.В. Оценка качества медицинской помощи больным мозговым инсультом по данным госпитального регистра в г. Иркутске. Сибирский Медицинский Журнал 2009; 2:68-70).
18. Shahparonov NV, Kadykov AS. Features rehabilitation in elderly patients with stroke. Consilium Medicum Ukraina 2010; 4(4): 32-5. Russian (Шахпаронова Н.В., Кадыков А.С. Особенности реабилитации больных пожилого возраста, перенесших инсульт. Consilium Medicum Ukraina 2010; 4(4):32-35).
19. Hart R.G., Benavente O., McBride R., Pearce L. A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
20. Suslinа ZA, Fonyakin AV, Geraskina LA, et al. Practical cardioneurology. Moscow: IMA-Press; 2010. Russian (Суслина З.А., Фонякин А.В., Гераскина Л.А. и др. Практическая кардионеврология. М.: ИМА-ПРЕСС; 2010).
21. McBride D, Brüggenjürgen B, Roll S, et al. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. Journal of Thrombosis and Thrombolysis 2007, 24(1):65-72.
22. Belousov YB, Mareev VY, Yavelov IS. et. al. Clinical and economic analysis of the effectiveness of dabigatranetexilate compared with warfarin in terms of prevention of cardiovascular complications in patients with non-valvular atrial fibrillation. Ration Pharmacother Cardiol 2012; 1:37-44. Russian (БелоусовЮ.Б., МареевВ.Ю., Явелов И.С. идр. Клинико-экономический анализ эффективности дабигатрана этексилата в сравнении с варфарином в аспекте профилактики сердечно-сосудистых осложнений у пациентов с неклапанной фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии 2012;1:37-44).
23. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72.
24. Granger ChB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365:981-92.
25. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
27. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365:883-91.
28. Kurbanov RD, Zakirov NU, Irisov DB, et al. Prediction of Thromboembolism in Patients with long-lasting atrial fibrillation. Evraziyskiy Kardiologicheskiy Zhurnal 2014;1:90-94. Russian (Курбанов Р.Д., Закиров Н.У., Ирисов Д.Б., Хусанов Ш.С. Прогнозирование развития тромбэмболических осложнений у больных с длительно существующими формами фибрилляции предсердий. Евразийский Кардиологический Журнал 2014;1:90-4).
29. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
30. Schrander J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosaran compared with netrendipine for secondary prevention (MOSES study). Stroke 2005;36:1218-26.
31. Hanley D.F., Hacke W. Advances in Stroke 2003. Critical Care and Emergency Medicine Neurology. Stroke 2004;35:365-6.
32. Schrader J, Luders S, Kulschewski A, et al. Original Contributions The ACCESS Study Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703.
33. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.
34. Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355: 549-59.
35. De Deyn PP, Reuck JD, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 1997;28(12):2347-52.
36. Ratmanova A. Ischemic stroke and neuroprotection: the search continues. Medicine Review 2008; 3(03):38-44. Russian (Ратманова А. Ишемический инсульт и нейропротекция: поиск продолжается. Medicine Review 2008;3(03):38-44).
37. Recommendations for Imaging of Acute Ischemic Stroke. A Scientific Statement From the American Heart Association. Stroke 2009;40:3646-78.
Review
For citations:
Mikheeva N.V., Reshetko O.V., Furman N.V. PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2014;10(6):617-624. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-617-624
Views:
704
Email this article 